Heartlight

US-based Boston Biomedical Associates (BBA) has entered into partnership with CardioFocus, to help them in securing premarket approval (PMA) from the US Food and Drug Administration (FDA) for its HeartLight Endoscopic Ablation System designed to treat patients with paroxysmal atrial fibrillation (AF).

AF is the most common form of cardiac arrhythmia, affecting more than 33 million people globally, and an estimated 2.7-6.1 million people in the US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The HeartLight System is said to be the first catheter ablation system that enables the electrophysiologist to monitor the delivery of therapeutic laser energy, for the first time under direct visual guidance, to electrically and durably isolate the pulmonary veins (PVs).

"The creativity applied to address the complexities in the approval process and to develop a clinical study report that resulted in the PMA approval in this short time span was truly impressive."

It features a compliant balloon catheter designed to facilitate flexibility during the procedure and is compatible to a range of PV ostiums (openings) irrespective of individual patient anatomy, and a laser energy source for more efficient and precise ablation.

The HeartLight system accounts for wide usage for the treatment of paroxysmal AF at centres throughout Europe, administered to more than 3400 patients across the world.

See Also:

BBA consulting services principal Michelle Michela said: "The creativity applied to address the complexities in the approval process and to develop a clinical study report that resulted in the PMA approval in this short time span was truly impressive."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

After securing the PMA approval, CardioFocus will emerge as one of the manufacturers possessing a specific indication for catheter ablation therapy of paroxysmal AF and will seek to commercialise the HeartLight System in the US.

Image: Rhythm tracing in atrial fibrillation and a drawing of a heart. Photo: courtesy of BruceBlaus.